Efstathios Kastritis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1528920/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2023, 30, 3-17.	3.0	22
2	A randomized phase 3 study of ixazomib–dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. Leukemia, 2022, 36, 225-235.	7.2	29
3	Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. Clinical and Experimental Medicine, 2022, 22, 319-323.	3.6	30
4	Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenstr¶m's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study. Journal of Clinical Oncology, 2022, 40, 40-51.	1.6	22
5	Utilization and tolerance of beta-blockers among patients with AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 31-37.	3.0	2
6	Myeloma patients with COVIDâ€19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine. British Journal of Haematology, 2022, 196, 356-359.	2.5	18
7	Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study. Journal of Clinical Oncology, 2022, 40, 52-62.	1.6	62
8	Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients. Prostate Cancer and Prostatic Diseases, 2022, 25, 117-118.	3.9	7
9	Population Pharmacokinetics and Exposureâ€Response Modeling of Daratumumab Subcutaneous Administration in Patients With Lightâ€Chain Amyloidosis. Journal of Clinical Pharmacology, 2022, 62, 656-669.	2.0	7
10	miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome. British Journal of Cancer, 2022, 126, 79-90.	6.4	11
11	Kinetics of $\langle scp \rangle$ antiâ \in SARSâ \in CoV $\langle scp \rangle$ â \in 2 neutralizing antibodies development after $\langle scp \rangle$ BNT162b2 $\langle scp \rangle$ vaccination in patients with amyloidosis and the impact of therapy. American Journal of Hematology, 2022, 97, E27.	4.1	5
12	Determination of <i>MYD88L265P</i> mutation fraction in IgM monoclonal gammopathies. Blood Advances, 2022, 6, 189-199.	5.2	10
13	Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 1-7.	3.0	42
14	Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis. Biomedicines, 2022, 10, 204.	3.2	7
15	The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells. Biomedicines, 2022, 10, 209.	3.2	8
16	How I treat relapsed multiple myeloma. Blood, 2022, 139, 2904-2917.	1.4	16
17	Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy. Blood, 2022, 139, 1409-1412.	1.4	28
18	Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222. Biomedicines, 2022, 10, 338.	3.2	21

#	Article	IF	CITATIONS
19	Future Developments in the Treatment of AL Amyloidosis. Hemato, 2022, 3, 131-152.	0.6	2
20	Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals. HemaSphere, 2022, 6, e677.	2.7	17
21	High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia. Blood Advances, 2022, 6, 3655-3658.	5.2	4
22	Healthâ€related quality of life in patients with <scp>light chain</scp> amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the <scp>ANDROMEDA</scp> study. American Journal of Hematology, 2022, 97, 719-730.	4.1	3
23	The utility of splenic imaging parameters in cardiac magnetic resonance for the diagnosis of immunoglobulin light-chain amyloidosis. Insights Into Imaging, 2022, 13, 55.	3.4	7
24	Comparison of MRI Features of Fat Fraction and ADC for Early Treatment Response Assessment in Participants with Multiple Myeloma. Radiology, 2022, 304, 137-144.	7.3	18
25	Plasma Metabolomic Alterations Induced by COVID-19 Vaccination Reveal Putative Biomarkers Reflecting the Immune Response. Cells, 2022, 11, 1241.	4.1	14
26	Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. Trends in Molecular Medicine, 2022, 28, 542-554.	6.7	104
27	Monoclonal antibody-based therapies for Waldenström's macroglobulinemia. Leukemia Research Reports, 2022, 17, 100324.	0.4	1
28	Immunogenic Cell Death, DAMPs and Prothymosin $\hat{I}\pm$ as a Putative Anticancer Immune Response Biomarker. Cells, 2022, 11, 1415.	4.1	34
29	Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients. Journal of Clinical Medicine, 2022, 11, 3088.	2.4	2
30	Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study "REBUILD― Cancers, 2022, 14, 2768.	3.7	6
31	Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls. Journal of Clinical Medicine, 2022, 11, 3355.	2.4	4
32	Determining patterns of vascular function and structure in wild-type transthyretin cardiac amyloidosis. A comparative study. International Journal of Cardiology, 2022, 363, 102-110.	1.7	1
33	Chromosome 1q21 aberrations identify ultra <scp>highâ€fisk</scp> myeloma with prognostic and clinical implications. American Journal of Hematology, 2022, 97, 1142-1149.	4.1	10
34	Birtamimab in patients with Mayo stage IV AL amyloidosis: Rationale for confirmatory affirm-AL phase 3 study Journal of Clinical Oncology, 2022, 40, TPS8076-TPS8076.	1.6	6
35	Next generation flow cytometry for MRD detection in patients with AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 19-23.	3.0	22
36	Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 3-11.	3.0	18

#	Article	IF	CITATIONS
37	Emerging treatment strategies for COVID-19 infection. Clinical and Experimental Medicine, 2021, 21, 167-179.	3.6	232
38	Daratumumabâ€based therapy for patients with monoclonal gammopathy of renal significance. British Journal of Haematology, 2021, 193, 113-118.	2.5	15
39	Screening for Gaucher disease among patients with plasma cell dyscrasias. Leukemia and Lymphoma, 2021, 62, 761-763.	1.3	2
40	Cardiac amyloidosis: in search of the ideal diagnostic tool. Herz, 2021, 46, 9-14.	1.1	7
41	Cardiac amyloidosis presenting with coronary artery embolization. Reviews in Cardiovascular Medicine, 2021, 22, 883.	1.4	1
42	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. Journal of Biomedical Science, 2021, 28, 9.	7.0	167
43	Mutation-dependent treatment approaches for patients with complex multiple myeloma. Expert Review of Precision Medicine and Drug Development, 2021, 6, 189-201.	0.7	Ο
44	Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study. Leukemia, 2021, 35, 1418-1427.	7.2	15
45	Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit. Cancers, 2021, 13, 763.	3.7	3
46	Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study. Cancers, 2021, 13, 1257.	3.7	9
47	SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response. Vaccines, 2021, 9, 207.	4.4	12
48	Exercise-Induced Changes in Tumor Growth via Tumor Immunity. Sports, 2021, 9, 46.	1.7	7
49	Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection. Microorganisms, 2021, 9, 546.	3.6	14
50	Whole-Body Low-Dose CT in Multiple Myeloma: Diagnostic Value of Appendicular Medullary Patterns of Attenuation. American Journal of Roentgenology, 2021, 216, 742-751.	2.2	8
51	Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood, 2021, 137, 3674-3676.	1.4	130
52	Nephrotoxicity in patients with cancer treated with immune checkpoint inhibitors Journal of Clinical Oncology, 2021, 39, e14558-e14558.	1.6	0
53	Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study Journal of Clinical Oncology, 2021, 39, 8003-8003.	1.6	15
54	Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 361-367.	0.4	10

#	Article	IF	CITATIONS
55	Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. Blood, 2021, 138, 2002-2005.	1.4	27
56	Managing complications secondary to Waldenström's macroglobulinemia. Expert Review of Hematology, 2021, 14, 1-12.	2.2	0
57	The Spectrum of Ocular Manifestations in Patients with Waldenström's Macroglobulinemia. Ocular Immunology and Inflammation, 2021, , 1-10.	1.8	5
58	A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma. Cancers, 2021, 13, 3877.	3.7	12
59	Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. Journal of Infection, 2021, 83, 1-16.	3.3	127
60	High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. Vaccines, 2021, 9, 712.	4.4	25
61	The Utility of Non-LGE Cardiac Magnetic Resonance Imaging Parameters in the Diagnosis of Cardiac Amyloidosis. Heart Lung and Circulation, 2021, 30, e137-e138.	0.4	2
62	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. New England Journal of Medicine, 2021, 385, 46-58.	27.0	268
63	Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis. HemaSphere, 2021, 5, e614.	2.7	7
64	Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. Cells, 2021, 10, 1942.	4.1	38
65	Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients. Cancers, 2021, 13, 4047.	3.7	8
66	Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naìve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Medicine, 2021, 19, 208.	5.5	52
67	The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer Journal, 2021, 11, 138.	6.2	103
68	Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study. Cancers, 2021, 13, 4480.	3.7	44
69	Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study. Blood Advances, 2021, 5, 4398-4405.	5.2	39
70	Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 259-266.	3.0	8
71	Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-Analyses. Journal of Clinical Medicine, 2021, 10, 4179.	2.4	10
72	Patterns of pharmaceuticals use during the first wave of COVID-19 pandemic in Athens, Greece as revealed by wastewater-based epidemiology. Science of the Total Environment, 2021, 798, 149014.	8.0	76

#	Article	IF	CITATIONS
73	SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors. Breast, 2021, 60, 58-61.	2.2	15
74	Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis. Heart Failure Reviews, 2021, 26, 861-879.	3.9	16
75	A prognostic index predicting survival in transformed Waldenström macroglobulinemia. Haematologica, 2021, 106, 2940-2946.	3.5	11
76	Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. Viruses, 2021, 13, 26.	3.3	26
77	Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals. Life, 2021, 11, 1077.	2.4	25
78	Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors. Vaccines, 2021, 9, 1148.	4.4	10
79	Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection. Frontiers in Immunology, 2021, 12, 746203.	4.8	10
80	Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study. Cancers, 2021, 13, 5057.	3.7	6
81	Biomarkers in AL Amyloidosis. International Journal of Molecular Sciences, 2021, 22, 10916.	4.1	7
82	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematology,the, 2021, 8, e934-e946.	4.6	46
83	Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis. Therapeutic Advances in Hematology, 2021, 12, 204062072110583.	2.5	5
84	OAB-036: Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S23-S24.	0.4	0
85	OAB-034: Evaluating the impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis: subanalyses from the ANDROMEDA study. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S22.	0.4	2
86	P-127: Patients with Multiple Myeloma on treatment with Anti-CD38 or Anti-BCMA agents have a suboptimal humoral response following COVID-19 vaccination. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S104.	0.4	0
87	P-009: Assessing the predictive utility of hematologic response for overall survival in patients with newly diagnosed AL amyloidosis: a systematic literature review and meta-analysis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S43-S44.	0.4	0
88	Kinetics of Anti-Sars-Cov-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. Blood, 2021, 138, 4202-4202.	1.4	0
89	Patients with Multiple Myeloma and Prior COVID-19 Have Superior Antibody Responses Against Sars-Cov-2 Compared with Fully Vaccinated Myeloma Patients with the BNT162b2 Vaccine. Blood, 2021, 138, 3802-3802.	1.4	0
90	Single Cell Analysis of MYD88 L265P and MYD88 WT Waldenström Macroglobulinemia Patients. Blood, 2021, 138, 1599-1599.	1.4	0

#	Article	IF	CITATIONS
91	Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival. Blood, 2021, 138, 2720-2720.	1.4	4
92	Impact of Daratumumab-Containing Induction on Stem Cell Mobilization and Collection, Engraftment and Hospitalization Parameters Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. Blood, 2021, 138, 3886-3886.	1.4	5
93	Evaluation of Efficacy and Immune Modulation Associated with the Addition of IMiDs to Daratumumab Backbone in Patients Refractory to Both Drug Classes. Blood, 2021, 138, 1668-1668.	1.4	1
94	Genomic Profiling of Smoldering Multiple Myeloma Classifies Molecular Groups with Distinct Pathogenic Phenotypes and Clinical Outcomes. Blood, 2021, 138, 723-723.	1.4	0
95	The Genomic Landscape of Waldenström Macroglobulinemia Reveals Sustained Germinal Center Activity and Late-Developing Copy Number Aberrations. Blood, 2021, 138, 2394-2394.	1.4	0
96	Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial. Blood, 2021, 138, 4771-4771.	1.4	0
97	Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients. Blood, 2021, 138, 153-153.	1.4	6
98	High Frequency of CNS Involvement in Transformed Waldenström Macroglobulinemia. Blood, 2021, 138, 2526-2526.	1.4	1
99	Antibody Response after Vaccination for Sars-Cov-2 in Patients with AL Amyloidosis and the Impact of Therapy. Blood, 2021, 138, 3799-3799.	1.4	Ο
100	Patients with Multiple Myeloma on Anti-CD38 or Anti-BCMA Based Regimens and Patients with Waldenstrom's Macroglobulinemia Under Rituximab or BTK Inhibitors Have a Poor Humoral Response Following COVID-19 Vaccination. Blood, 2021, 138, 3791-3791.	1.4	0
101	Graded Renal Response Criteria for Light Chain (AL) Amyloidosis. Blood, 2021, 138, 2721-2721.	1.4	5
102	Safety and Efficacy of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Outcomes of the Phase 2 Daria Study. Blood, 2021, 138, 2737-2737.	1.4	1
103	Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network. Blood, 2021, 138, 2730-2730.	1.4	6
104	De Novo AL Amyloidosis in Renal Allograft and Anti-CD38 Monoclonal Antibody Treatment. HemaSphere, 2021, 5, e665.	2.7	0
105	Impact of Daratumumab Monotherapy on Bone Metabolism Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor: Outcomes of the Phase 2 Rebuild Study. Blood, 2021, 138, 1672-1672.	1.4	0
106	Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study. Blood, 2021, 138, 159-159.	1.4	5
107	A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. Blood, 2021, 138, 2736-2736.	1.4	4
108	Mutations in the Alternative Complement Pathway in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy. Blood, 2021, 138, 2708-2708.	1.4	2

#	Article	IF	CITATIONS
109	Poor Neutralizing Antibody Responses in Patients with CLL, NHL and HL after Vaccination Against Sars-Cov-2; A Prospective Study in 132 Patients. Blood, 2021, 138, 3752-3752.	1.4	0
110	Changing Patterns of Symptomatic Myeloma after the Implementation of the 2014 IMWG Diagnostic Criteria and Reduced Early Mortality. Blood, 2021, 138, 1636-1636.	1.4	2
111	Efficacy and Safety of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment or on Dialysis: Final Analysis of the Phase 2 Dare Study. Blood, 2021, 138, 2729-2729.	1.4	1
112	tRNA Derivatives in Multiple Myeloma: Investigation of the Potential Value of a tRNA-Derived Molecular Signature. Biomedicines, 2021, 9, 1811.	3.2	8
113	Daratumumab for Immunoglobulin Light Chain Amyloidosis. Touch Reviews in Oncology & Haematology, 2021, 17, 79.	0.2	Ο
114	A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma. International Journal of Molecular Sciences, 2021, 22, 13144.	4.1	13
115	A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. Haematologica, 2020, 105, 201-208.	3.5	48
116	Multiple myeloma: Role of autologous transplantation. Cancer Treatment Reviews, 2020, 82, 101929.	7.7	42
117	Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 57-62.	0.4	10
118	Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematology,the, 2020, 7, e112-e121.	4.6	119
119	Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVIDâ€19ÂPandemic. HemaSphere, 2020, 4, e433.	2.7	11
120	Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Lancet Haematology,the, 2020, 7, e827-e837.	4.6	96
121	Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report. Life, 2020, 10, 214.	2.4	31
122	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. Blood Cancer Journal, 2020, 10, 93.	6.2	13
123	Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity. Cancers, 2020, 12, 2864.	3.7	12
124	Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction. Journal of Clinical Medicine, 2020, 9, 3201.	2.4	1
125	International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer Journal, 2020, 10, 102.	6.2	126
126	Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma. Cancers, 2020, 12, 2006.	3.7	15

#	Article	IF	CITATIONS
127	Organ-specific manifestations of COVID-19 infection. Clinical and Experimental Medicine, 2020, 20, 493-506.	3.6	351
128	Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. Journal of Clinical Oncology, 2020, 38, 3252-3260.	1.6	102
129	Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib. International Journal of Molecular Sciences, 2020, 21, 5185.	4.1	12
130	Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause. Leukemia and Lymphoma, 2020, 61, 3247-3250.	1.3	3
131	Editorial: Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches. Frontiers in Oncology, 2020, 10, 607571.	2.8	Ο
132	Response of an oncology unit in the midst of the COVID-19 outbreak. Journal of Oncology Pharmacy Practice, 2020, 26, 1947-1952.	0.9	1
133	Emerging drugs for the treatment of Waldenström macroglobulinemia. Expert Opinion on Emerging Drugs, 2020, 25, 433-444.	2.4	3
134	Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management. HemaSphere, 2020, 4, e454.	2.7	28
135	MM-167: Phenotypic and Prognostic Evaluation of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma Detected with Next-Generation Flow Cytometry (NGF). Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S297-S298.	0.4	0
136	Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients. Blood Cancer Journal, 2020, 10, 109.	6.2	21
137	Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma. Cancers, 2020, 12, 3245.	3.7	24
138	Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVIDâ€19 pandemic. British Journal of Haematology, 2020, 190, 346-357.	2.5	17
139	Long PFS of more than 7Âyears is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period. Annals of Hematology, 2020, 99, 1257-1264.	1.8	9
140	Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis. Leukemia and Lymphoma, 2020, 61, 2246-2249.	1.3	0
141	Solid Organ Transplantation in Amyloidosis. Acta Haematologica, 2020, 143, 352-364.	1.4	10
142	Efficacy of Panobinostat for the Treatment of Multiple Myeloma. Journal of Oncology, 2020, 2020, 1-11.	1.3	46
143	Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma. Blood Cancer Journal, 2020, 10, 25.	6.2	16
144	Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome. HemaSphere, 2020, 4, e381.	2.7	14

#	Article	IF	CITATIONS
145	Realâ€world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Grecoâ€Israeli collaborative myeloma working group. American Journal of Hematology, 2020, 95, 465-471.	4.1	9
146	Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes. Rheumatology International, 2020, 40, 1353-1360.	3.0	33
147	Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e905-e909.	0.4	9
148	JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer. European Journal of Cancer, 2020, 126, 125-135.	2.8	48
149	Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implications. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 103-110	3.0	11
150	Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 445-452.	0.4	23
151	Cellâ€free <scp>DNA</scp> analysis for the detection of <scp>MYD88</scp> and <scp>CXCR4</scp> mutations in <scp>IgM</scp> monoclonal gammopathies; an update with clinicopathological correlations. American Journal of Hematology, 2020, 95, E148-E150.	4.1	12
152	Hematological findings and complications of <scp>COVID</scp> â€19. American Journal of Hematology, 2020, 95, 834-847.	4.1	1,354
153	Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Annals of Hematology, 2020, 99, 1049-1061.	1.8	31
154	Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma. Annals of Hematology, 2020, 99, 1251-1255.	1.8	17
155	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. Blood Cancer Journal, 2020, 10, 40.	6.2	15
156	Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. Blood Advances, 2020, 4, 830-844.	5.2	54
157	Significant reduction in the visits to the emergency room department during the COVID-19 pandemic in a tertiary hospital in Greece. Medicine (United States), 2020, 99, e23845.	1.0	20
158	Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATETM Study. Blood, 2020, 136, 24-26.	1.4	19
159	Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Devamethasone with or without Daratumumah: Results from Andromeda, Blood, 2020, 136, 48-50	1.4	11
160	Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study. Blood, 2020, 136, 37-40.	1.4	5
161	Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda. Blood, 2020, 136, 44-45.	1.4	5
162	Rapid and Deep Hematologic Responses Are Associated with Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results from Andromeda. Blood, 2020, 136, 6-7.	1.4	5

#	Article	IF	CITATIONS
163	First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network. Blood, 2020, 136, 50-51.	1.4	12
164	Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First - Line Treatment of Waldenstrom's Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial. Blood, 2020, 136, 26-26.	1.4	13
165	Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood, 2020, 136, 71-80.	1.4	146
166	Ixazomib-dexamethasone (Ixa-Dex) vs physician's choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial Journal of Clinical Oncology, 2020, 38, 8546-8546.	1.6	7
167	Liver and Gastrointestinal Involvement. Hematology/Oncology Clinics of North America, 2020, 34, e1-e13.	2.2	5
168	IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure. Blood, 2020, 136, 12-12.	1.4	0
169	A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias. Blood, 2020, 136, 8-8.	1.4	Ο
170	Carfilzomib-Induced Hypertension Is Mediated By Ion Channel Dysregulation in the Kidneys; The Potent Role of AMP-Activated Kinase α. Blood, 2020, 136, 34-35.	1.4	1
171	Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study. Blood, 2020, 136, 48-49.	1.4	7
172	Short Daratumumab Consolidation in Patients with AL Amyloidosis or Lcdd Improves Complete Response Rates and Modifies Bone Marrow Microenvironment. Blood, 2020, 136, 25-25.	1.4	1
173	Efficacy and Tolerability of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Preliminary Results of the Phase 2 Daria Study. Blood, 2020, 136, 19-20.	1.4	0
174	Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study. Blood, 2020, 136, 29-29.	1.4	0
175	Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) As a Biomarker of Renal Outcomes in AL Amyloidosis. Blood, 2020, 136, 33-33.	1.4	1
176	Light Chain Deposition Disease: First Analysis of an International Study in 359 Patients. Blood, 2020, 136, 33-34.	1.4	0
177	The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both Agents. Blood, 2020, 136, 21-21.	1.4	4
178	Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study. Blood, 2020, 136, 11-11.	1.4	3
179	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. Blood, 2020, 136, 6-7.	1.4	0
180	Carfilzomib-Induced Cardiotoxicity in an In Vivo Model of Aging. Blood, 2020, 136, 18-18.	1.4	0

#	Article	IF	CITATIONS
181	T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: Longitudinal Analysis during 7 Cycle Follow-up of the Rebuild Phase 2 Study. Blood, 2020, 136, 28-28.	1.4	1
182	Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. Leukemia and Lymphoma, 2019, 60, 163-171.	1.3	11
183	Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis. Circulation Research, 2019, 125, 744-758.	4.5	22
184	<p>Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia</p> . Journal of Blood Medicine, 2019, Volume 10, 291-300.	1.7	13
185	Incidence of Skeletal-Related Events at Diagnosis and at the Time of First Relapse in 463 Patients with Multiple Myeloma Who Received First Line Treatment in a Single Center. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S333.	0.4	2
186	Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma. Expert Review of Anticancer Therapy, 2019, 19, 921-928.	2.4	8
187	Nonâ€lethal proteasome inhibition activates proâ€tumorigenic pathways in multiple myeloma cells. Journal of Cellular and Molecular Medicine, 2019, 23, 8010-8018.	3.6	4
188	Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma who Are Treated with Bortezomib-Based Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S325.	0.4	0
189	Primary Treatment of Light Chain (AL) Amyloidosis with Bortezomib, Lenalidomide and Dexamethasone (VRD). Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S331-S332.	0.4	0
190	How I treat Waldenström macroglobulinemia. Blood, 2019, 134, 2022-2035.	1.4	65
191	Hereditary systemic amyloidosis caused by K19T apolipoprotein C-II variant. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 52-53.	3.0	3
192	A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options. BMC Medical Genetics, 2019, 20, 23.	2.1	8
193	<p>Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a case–control study</p> . OncoTargets and Therapy, 2019, Volume 12, 4195-4202.	2.0	2
194	A revised international prognostic score system for Waldenström's macroglobulinemia. Leukemia, 2019, 33, 2654-2661.	7.2	53
195	A 50-Year-Long Study of Waldenstr¶m Macroglobulinemia. Mayo Clinic Proceedings, 2019, 94, 394-396.	3.0	1
196	Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. Journal of Clinical Oncology, 2019, 37, 1403-1411.	1.6	65
197	Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop. Scientific Reports, 2019, 9, 3245.	3.3	25
198	Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. Annals of Hematology, 2019, 98, 1427-1434.	1.8	9

#	Article	IF	CITATIONS
199	Bone marrow biopsy in lowâ€risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. American Journal of Hematology, 2019, 94, E146-E149.	4.1	11
200	Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy. HemaSphere, 2019, 3, e300.	2.7	20
201	Progression risk stratification of Asymptomatic Waldenström Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e38-e39.	0.4	0
202	Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. Blood Advances, 2019, 3, 4095-4103.	5.2	17
203	Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. Blood Advances, 2019, 3, 3002-3009.	5.2	37
204	Longitudinal Evaluation of Minimal Residual Disease in Patients with Multiple Myeloma who Achieve Complete Response After First Line Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e185-e186.	0.4	0
205	Clonal Heterogeneity and Immune Tumor Microenvironment in Waldenström Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e318-e319.	0.4	0
206	Primary Treatment of Light Chain (AL) Amyloidosis With Bortezomib, Lenalidomide and Dexamethasone (VRD) or with Bortezomib, Cyclophosphamide and Dexamethasone (VCD/CyBorD): efficacy and toxicity. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e320-e321.	0.4	1
207	Analysis of the genomic and transcriptomic landscape of chemoresistant multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e58-e59.	0.4	0
208	Real-world Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma in the Novel Therapeutic Era: A study of the Greco-Israeli Collaborative Myeloma Working Group. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e190-e191.	0.4	0
209	High-dimensional Clonal Heterogeneity and Immune Landscape in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e28-e29.	0.4	0
210	Synergistic Effect of Carfilzomib and Metformin in Vascular Plasticity. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e121-e122.	0.4	0
211	Treatment of Bing–Neel syndrome with first line sequential chemoimmunotherapy. Medicine (United) Tj ETQq1	1,0,7843 1.0	14 rgBT /Ove
212	Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e5-e6.	0.4	1
213	Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 23-28	0.4	2
214	Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates. American Journal of Hematology, 2019, 94, 400-407.	4.1	21
215	Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. Blood, 2019, 133, 710-723.	1.4	82
216	Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. International Journal of Cancer, 2019, 145, 559-568.	5.1	10

#	Article	IF	CITATIONS
217	Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. Leukemia and Lymphoma, 2019, 60, 619-628.	1.3	9
218	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nature Reviews Nephrology, 2019, 15, 45-59.	9.6	330
219	How We Manage Patients with Plasmacytomas. Current Hematologic Malignancy Reports, 2018, 13, 227-235.	2.3	10
220	Primary Systemic Amyloidosis. Hematologic Malignancies, 2018, , 221-245.	0.2	0
221	Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. Blood, 2018, 131, 1568-1575.	1.4	44
222	Denosumab for myeloma bone disease: ready for prime time?. Lancet Oncology, The, 2018, 19, 277-278.	10.7	3
223	Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 431-437.	0.4	5
224	Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. Blood Cancer Journal, 2018, 8, 31.	6.2	35
225	Rare manifestations of extramedullary myeloma: testicular plasmacytomas. Leukemia and Lymphoma, 2018, 59, 2002-2004.	1.3	6
226	The role of ibrutinib in Waldenström macroglobulinemia. Expert Opinion on Orphan Drugs, 2018, 6, 85-89.	0.8	0
227	The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. Blood, 2018, 131, 464-467.	1.4	54
228	Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or) Tj ETQq0 0 2018, 59, 983-987.	0 rgBT /O 1.3	verlock 10 Tf 4
229	Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 234-241.	3.0	24
230	Acalabrutinib in Patients (pts) with Waldenström Macroglobulinemia (WM). Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S285-S286.	0.4	1
231	Thalidomide for myeloma: still here?. Lancet Haematology,the, 2018, 5, e439-e440.	4.6	1
232	Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. Blood Cancer Journal, 2018, 8, 102.	6.2	23
233	Cardio-oncology: A Focus on Cardiotoxicity. European Cardiology Review, 2018, 13, 64.	2.2	65
234	Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, iv41-iv50.	1.2	63

#	Article	IF	CITATIONS
235	Ibrutinib/Rituximab versus Placebo/Rituximab: A Randomized, Phase 3 Trial in Waldenström's Macroglobulinemia (iNNOVATE). Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S283.	0.4	0
236	Prognostic factors for multiple myeloma in the era of novel therapies. Expert Review of Hematology, 2018, 11, 863-879.	2.2	28
237	Clinical Characteristics and Outcomes of Oligosecretory and Non-Secretory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S237-S238.	0.4	Ο
238	Waldenström Macroglobulinemia: Lessons Learned from Basic and Clinical Research. Hematology/Oncology Clinics of North America, 2018, 32, xiii-xiv.	2.2	0
239	Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Newly Diagnosed Chemotherapy NaÃ ⁻ ve Patients with Multiple Myeloma at Risk for Cancer-Associated Thrombosis. The Observational ROADMAT-CAT-MM Study. Clinical Lymphoma, Myeloma and Leukemia. 2018. 18. S235-S236.	0.4	0
240	Translocation (14;16) Positive Multiple Myeloma: Clinical Features and Survival Outcomes of a High-risk Population. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S250-S251.	0.4	0
241	Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia, 2018, 32, 2604-2616.	7.2	137
242	Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. Blood Cancer Journal, 2018, 8, 46.	6.2	39
243	Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. New England Journal of Medicine, 2018, 378, 2399-2410.	27.0	291
244	Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. Lancet Haematology,the, 2018, 5, e299-e309.	4.6	41
245	Managing myeloma with limited resources in the era of novel drugs. Leukemia and Lymphoma, 2018, 59, 2269-2270.	1.3	2
246	Proteasome Inhibitors in Waldenström Macroglobulinemia. Hematology/Oncology Clinics of North America, 2018, 32, 829-840.	2.2	11
247	Monoclonal Antibodies for Waldenström Macroglobulinemia. Hematology/Oncology Clinics of North America, 2018, 32, 841-852.	2.2	0
248	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia, 2018, 32, 1883-1898.	7.2	81
249	Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. Leukemia, 2018, 32, 2617-2625.	7.2	40
250	Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma. Blood Cancer Journal, 2018, 8, 42.	6.2	29
251	Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e493-e499.	0.4	20
252	Ibrutinib Treatment in Waldenström's Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATETM Study. Blood, 2018, 132, 149-149.	1.4	20

#	Article	IF	CITATIONS
253	Carfilzomib-Associated Renal Toxicity Is Common and Unpredictable: An Analysis of 114 Patients. Blood, 2018, 132, 1966-1966.	1.4	3
254	Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group. Blood, 2018, 132, 3295-3295.	1.4	1
255	Acalabrutinib in patients (pts) with Waldenström macroglobulinemia (WM) Journal of Clinical Oncology, 2018, 36, 7501-7501.	1.6	11
256	Subcutaneous daratumumab (DARA SC) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients (Pts) with newly diagnosed amyloid light chain (AL) amyloidosis: Safety run-in results of andromeda Journal of Clinical Oncology, 2018, 36, 8011-8011.	1.6	5
257	Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO) Journal of Clinical Oncology, 2018, 36, TPS8059-TPS8059.	1.6	8
258	How I treat elderly patients with plasma cell dyscrasias. Aging, 2018, 10, 4248-4268.	3.1	9
259	Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent. Oncotarget, 2018, 9, 17797-17809.	1.8	10
260	Evaluation of pre-mir-34a rs72631823 single nucleotide polymorphism in triple negative breast cancer: A case-control study. Oncotarget, 2018, 9, 36906-36913.	1.8	7
261	How I treat rituximab refractory patients with WM. Oncotarget, 2018, 9, 36824-36825.	1.8	6
262	Ibrutinib for rituximab-refractory Waldenström macro-globulinemia. Oncotarget, 2018, 9, 12536-12537.	1.8	1
263	Randomized phase 3 trial of ibrutinib/rituximab vs placebo/rituximab in Waldenström's macroglobulinemia Journal of Clinical Oncology, 2018, 36, 8003-8003.	1.6	Ο
264	Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenstrom's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group. Blood, 2018, 132, 1978-1978.	1.4	1
265	Carfilzomib Induces Acute Endothelial Dysfunction Which Correlates with the Occurrence of Cardiovascular Events. Blood, 2018, 132, 3247-3247.	1.4	О
266	Progression Risk-Based Classification of Asymptomatic Waldenström Macroglobulinemia. Blood, 2018, 132, 150-150.	1.4	1
267	Metformin Restores AMPK Alpha-Mediated Autophagy and Prevents Carfilzomib-Induced Cardiotoxicity In Vivo. Blood, 2018, 132, 3214-3214.	1.4	0
268	Consolidation with a Short Course of Daratumumab Improves Complete Response Rates in Patients with AL Amyloidosis or Lcdd. Blood, 2018, 132, 3246-3246.	1.4	0
269	Functional Cure, Defined As PFS of More Than 7 Years, Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents; A Single-Center Experience over 20-Year Period. Blood, 2018, 132, 1968-1968.	1.4	1
270	Emerging treatment approaches for myeloma-related bone disease. Expert Review of Hematology, 2017, 10, 217-228.	2.2	13

#	Article	IF	CITATIONS
271	Efficacy and safety of elotuzumab for the treatment of multiple myeloma. Expert Opinion on Drug Safety, 2017, 16, 1-9.	2.4	4
272	Investigation and management of IgM and Waldenströmâ€associated peripheral neuropathies: recommendations from the <scp>IWWM</scp> â€8 consensus panel. British Journal of Haematology, 2017, 176, 728-742.	2.5	58
273	Prognosis and risk assessment in AL amyloidosis - There and back again. British Journal of Haematology, 2017, 177, 343-345.	2.5	1
274	Indirubins: A Potential Therapeutic Target in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e40-e41.	0.4	1
275	Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit. Blood Cancer Journal, 2017, 7, e571-e571.	6.2	33
276	Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia, 2017, 31, 2443-2448.	7.2	259
277	Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib. Blood Cancer Journal, 2017, 7, e570-e570.	6.2	31
278	Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy. Leukemia and Lymphoma, 2017, 58, 2304-2309.	1.3	17
279	Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy. American Journal of Hematology, 2017, 92, 632-639.	4.1	48
280	Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma. Haematologica, 2017, 102, 593-599.	3.5	72
281	lbrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncology, The, 2017, 18, 241-250.	10.7	212
282	Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia. Expert Opinion on Investigational Drugs, 2017, 26, 197-205.	4.1	12
283	Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens. Leukemia and Lymphoma, 2017, 58, 1832-1839.	1.3	24
284	BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. Blood, 2017, 129, 456-459.	1.4	62
285	Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. Haematologica, 2017, 102, 43-51.	3.5	112
286	A Revised Staging System for Waldenström's Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S332-S333.	0.4	0
287	Daratumumab combinations: what can we learn?. Blood, 2017, 130, 957-958.	1.4	3
288	Clonal evolution is a prognostic factor for the clinical progression of monoclonal B-cell lymphocytosis. Blood Cancer Journal, 2017, 7, e597-e597.	6.2	8

#	Article	IF	CITATIONS
289	The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies. European Journal of Haematology, 2017, 99, 449-458.	2.2	6
290	Low circulating mannan-binding lectin levels correlate with increased frequency and severity of febrile episodes in myeloma patients who undergo ASCT and do not receive antibiotic prophylaxis. Bone Marrow Transplantation, 2017, 52, 1537-1542.	2.4	2
291	Increased Semaphorin-4D and Plexin-B1 Levels in Multiple Myeloma Patients May Contribute to Osteolytic Bone Disease. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S332.	0.4	0
292	Addition of Cyclophosphamide and Higher Doses of Dexamethasone Do Not Improve Outcomes of Patients With AL amyloidosis Treated With Bortezomib. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e65-e66.	0.4	0
293	Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT without Dexamethasone and Bisphosphonates: Final Analysis of a Prospective Study. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e143-e144.	0.4	0
294	Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. European Journal of Haematology, 2017, 99, 409-414.	2.2	37
295	RAD Regimen Increases Bone Formation and Reduces Bone Resorption and Angiogenesis in Patients with Newly Diagnosed Myeloma: Results of a Phase 2 Study. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e143.	0.4	0
296	Growth Differentiation Factor 15 (GDF-15) Is a New Biomarker for Overall Survival and Renal Outcomes in Patients with Light Chain (AL) Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e40.	0.4	0
297	Outcomes of Consecutive Patients With Newly Diagnosed Myeloma Requiring Dialysis: Dialysis Independence is Associated with Rapid Myeloma Response and Predicts for Longer Survival. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e62-e63.	0.4	0
298	Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma. Annals of Hematology, 2017, 96, 1707-1714.	1.8	7
299	An overview of the role of carfilzomib in the treatment of multiple myeloma. Expert Opinion on Pharmacotherapy, 2017, 18, 1883-1897.	1.8	23
300	Prior Lenalidomide Resistance and the Impact of IMiD-free Interval in Patients Treated with Pomalidomide and Dexamethasone. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e115-e116.	0.4	0
301	Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia. Leukemia and Lymphoma, 2017, 58, 1506-1508.	1.3	9
302	Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple Myeloma. Radiology, 2017, 282, 484-493.	7.3	81
303	Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome. Hematological Oncology, 2017, 35, 734-740.	1.7	6
304	Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains. , 2017, , 239-261.		0
305	Immunomodulatory Agents and Proteasome Inhibitors in Waldenstrom's Macroglobulinemia. , 2017, , 335-343.		0
306	Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events. Scientific Reports, 2017, 7, 17802.	3.3	17

#	Article	IF	CITATIONS
307	Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Blood Advances, 2017, 1, 449-454.	5.2	89
308	Disease control should be the goal of therapy for WM patients. Blood Advances, 2017, 1, 2483-2485.	5.2	5
309	Successful treatment with lenalidomide dexamethasone for second relapse of a patient with non-secretory multiple myeloma with extramedullary liver plasmacytomas: A case report. Hematology & Medical Oncology, 2017, 2, .	0.1	1
310	Recent advances in the management of <scp>AL</scp> Amyloidosis. British Journal of Haematology, 2016, 172, 170-186.	2.5	88
311	Bortezomibâ€based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. American Journal of Hematology, 2016, 91, 499-502.	4.1	73
312	Proteasome inhibitor associated thrombotic microangiopathy. American Journal of Hematology, 2016, 91, E348-52.	4.1	95
313	Central nervous system involvement by multiple myeloma: A multiâ€institutional retrospective study of 172 patients in daily clinical practice. American Journal of Hematology, 2016, 91, 575-580.	4.1	83
314	A review of the venous thrombotic issues associated with multiple myeloma. Expert Review of Hematology, 2016, 9, 695-706.	2.2	21
315	Emerging antibodies for the treatment of multiple myeloma. Expert Opinion on Emerging Drugs, 2016, 21, 225-237.	2.4	25
316	Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 335-340.	0.4	16
317	Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis. Blood, 2016, 128, 405-409.	1.4	37
318	Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood, 2016, 128, 1321-1328.	1.4	161
319	Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis. Journal of Medicinal Chemistry, 2016, 59, 8787-8803.	6.4	41
320	Current therapy guidelines for Waldenstrom's macroglobulinaemia. Best Practice and Research in Clinical Haematology, 2016, 29, 194-205.	1.7	5
321	Evaluation of the Revised International Staging System (R-ISS) in an Independent Cohort of Unselected Patients with Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S75.	0.4	Ο
322	High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma. Blood Cancer Journal, 2016, 6, e482-e482.	6.2	16
323	Newly Diagnosed Multiple Myeloma is Associated with Hypercoagulability and High Risk of VTE The ROADMAP Study. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S76-S77.	0.4	0
324	<i><scp>TLR</scp>4/<scp>TIRAP</scp></i> polymorphisms are associated with progression and survival of patients with symptomatic myeloma. British Journal of Haematology, 2016, 172, 44-47.	2.5	8

#	Article	IF	CITATIONS
325	Recent Data Supporting Novel Management Strategies for Patients With Multiple Myeloma. JAMA Oncology, 2016, 2, 1261.	7.1	1
326	Current treatments for renal failure due to multiple myeloma. Expert Opinion on Pharmacotherapy, 2016, 17, 2165-2177.	1.8	28
327	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology, The, 2016, 17, e328-e346.	10.7	1,866
328	Managing renal complications in multiple myeloma. Expert Review of Hematology, 2016, 9, 839-850.	2.2	14
329	Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. British Journal of Haematology, 2016, 175, 77-86.	2.5	61
330	Carfilzomib for treating myeloma. Expert Opinion on Orphan Drugs, 2016, 4, 989-999.	0.8	2
331	Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment. Blood Cancer Journal, 2016, 6, e428-e428.	6.2	19
332	Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics. Annals of Oncology, 2016, 27, 233-240.	1.2	13
333	The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. Oncologist, 2016, 21, 333-342.	3.7	28
334	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. Journal of Clinical Oncology, 2016, 34, 1544-1557.	1.6	294
335	Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma. Leukemia and Lymphoma, 2016, 57, 1776-1780.	1.3	3
336	Primary failure of bortezomib in newly diagnosed multiple myeloma – understanding the magnitude, predictors, and significance. Leukemia and Lymphoma, 2016, 57, 1382-1388.	1.3	10
337	Neutrophil Gelatinase–Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 29-35.	0.4	16
338	Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with WaldenströM's Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years. Blood, 2016, 128, 2957-2957.	1.4	1
339	Pomalidomide with Low Dose Dexamethasone Is Effective Irrespective of Primary or Secondary Resistance to Lenalidomide but the IMiD-Free Interval Is Important. Blood, 2016, 128, 3310-3310.	1.4	1
340	Cardiac and Renal Complications of Carfilzomib Therapy in Patients with Multiple Myeloma. Blood, 2016, 128, 4491-4491.	1.4	2
341	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. Blood, 2016, 128, 646-646.	1.4	37
342	Growth Differentiation Factor-15 (GDF-15) Is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chain (AL) Amyloidosis. Blood, 2016, 128, 648-648.	1.4	1

#	Article	IF	CITATIONS
343	Glomerular expression of matrix metalloproteinases in AL-amyloidosis and association with renal function at the time of kidney biopsy. Clinical Nephrology, 2016, 85 (2016), 44-54.	0.7	7
344	Circulating Adiponectin and Markers of Endothelial and Cardiovascular Dysfunction Correlate with Disease Burden in Newly Diagnosed Patients with Multiple Myeloma; Increase of Adiponectin after Bortezomib- and IMiD-Based Regimens. Blood, 2016, 128, 4446-4446.	1.4	0
345	Lenalidomide, Adriamycin, and Dexamethasone (RAD) As Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Transplantation (ASCT): A Phase 2 Study from the Greek Myeloma Study Group. Blood, 2016, 128, 4488-4488.	1.4	0
346	Survivorship in WM: Identification of Factors Associated with Survival of More Than a Decade and with Early WM-Related Death. Blood, 2016, 128, 2954-2954.	1.4	0
347	Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. Blood, 2016, 128, 4414-4414.	1.4	0
348	Indirubins: A Potential Therapeutic Target in Multiple Myeloma. Blood, 2016, 128, 3259-3259.	1.4	0
349	Real-World Data on Clinical Characteristics, Prognosis and Outcome of Primary Plasma Cell Leukemia: A Study of the Greek Myeloma Study Group in the Era of Novel Agents. Blood, 2016, 128, 4490-4490.	1.4	0
350	Addition of Cyclophosphamide and Higher Doses of Dexamethasone Do Not Improve Outcomes of Patients with AL Amyloidosis Treated with Bortezomib. Blood, 2016, 128, 4500-4500.	1.4	0
351	Outcomes of Newly Diagnosed Myeloma Patients Requiring Dialysis: Dialysis Independence Is Associated with Rapid Myeloma Response and Predicts for Longer Survival. Blood, 2016, 128, 4492-4492.	1.4	Ο
352	Longâ€ŧerm outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. American Journal of Hematology, 2015, 90, E60-5.	4.1	55
353	Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy. Haematologica, 2015, 100, e446-e449.	3.5	44
354	Treatment options for relapsed and refractory multiple myeloma. Blood, 2015, 125, 3085-3099.	1.4	136
355	Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study. Blood, 2015, 126, 1392-1394.	1.4	108
356	Diagnosis of monoclonal gammopathy of renal significance. Kidney International, 2015, 87, 698-711.	5.2	339
357	An update on the use of lenalidomide for the treatment of multiple myeloma. Expert Opinion on Pharmacotherapy, 2015, 16, 1865-1877.	1.8	9
358	Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. Leukemia and Lymphoma, 2015, 56, 1723-1726.	1.3	19
359	Amyloid-Beta (1-40) and the Risk of Death From Cardiovascular Causes in Patients With Coronary Heart Disease. Journal of the American College of Cardiology, 2015, 65, 904-916.	2.8	91
360	Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging. Blood Cancer Journal, 2015, 5, e319-e319.	6.2	15

#	Article	IF	CITATIONS
361	Appraising myc involvement in high risk myeloma. Leukemia and Lymphoma, 2015, 56, 551-552.	1.3	4
362	European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. Haematologica, 2015, 100, 1254-1266.	3.5	289
363	Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience. Annals of Hematology, 2015, 94, 2033-2042.	1.8	43
364	Generation of a Large Observational Pan-European Data Platform for Treatment and Outcome Patterns in Patients with Waldenstrom's Macroglobulinemia. Blood, 2015, 126, 2096-2096.	1.4	3
365	Diffusion-Weighted Imaging Improves Accuracy in the Diagnosis of MRI Patterns of Marrow Involvement in Newly Diagnosed Myeloma: Results of a Prospective Study in 99 Patients. Blood, 2015, 126, 4178-4178.	1.4	12
366	Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study. Blood, 2015, 126, 4201-4201.	1.4	3
367	Thrombotic Microangiopathy in Multiple Myeloma. Blood, 2015, 126, 5317-5317.	1.4	3
368	Abstract 2004: Phenotypic and molecular characterization of inter- and intraclonal heterogeneity in multiple myeloma and Waldenstrom macroglobulinemia. , 2015, , .		0
369	The patient with myeloma. , 2015, , 1276-1291.		Ο
370	Bortezomib-Based Triplets Are Associated with a High Probability of Dialysis Independence and Rapid Renal Recovery in Newly Diagnosed Myeloma Patients with Severe Renal Failure or Those Requiring Dialysis. Blood, 2015, 126, 1832-1832.	1.4	0
371	Analysis of Molecular-Cellular Responses to Proteasome Inhibitors in Multiple Myeloma Patients; A Translational Approach of Proteasome Inhibitors In Vivo Effects from the Drosophila Experimental Model to Humans. Blood, 2015, 126, 3250-3250.	1.4	0
372	The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis. Blood, 2015, 126, 3049-3049.	1.4	0
373	Prospective Evaluation of Blood Pressure Monitoring and Baroreceptor Reflex Sensitivity (BRS) in Patients with AL Amyloidosis: Prognostic and Pathophysiologic Implications. Blood, 2015, 126, 3054-3054.	1.4	Ο
374	Validation of the Novel Criteria for the Definition of Symptomatic Myeloma: A Single Center Experience in 216 Patients with the Previous Diagnosis of Asymptomatic Disease. Blood, 2015, 126, 4251-4251.	1.4	0
375	Newly Diagnosed Multiple Myeloma Is Associated with Enhanced TF Pathway Activation, Thrombin Generation and Increased Concentration of Procoagulant Microparticles. Blood, 2015, 126, 1074-1074.	1.4	Ο
376	Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity. Blood, 2015, 126, 4188-4188.	1.4	1
377	Real-World Prospective Evaluation of Different Geriatric Assessment Tools in Unselected Elderly Patients with Symptomatic Myeloma. Blood, 2015, 126, 4242-4242.	1.4	0
378	Conservative Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients. International Journal of Dentistry, 2014, 2014, 1-7.	1.5	20

#	Article	IF	CITATIONS
379	Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. Leukemia and Lymphoma, 2014, 55, 2018-2023.	1.3	57
380	VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT. Leukemia, 2014, 28, 928-934.	7.2	32
381	Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents. European Journal of Haematology, 2014, 92, 308-312.	2.2	31
382	Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. Leukemia, 2014, 28, 2075-2079.	7.2	57
383	The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma. Leukemia, 2014, 28, 2402-2403.	7.2	115
384	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology, The, 2014, 15, e538-e548.	10.7	3,343
385	Hematologic Response and Stabilization of Renal Function in a Patient With Light Chain Deposition Disease After Lenalidomide Treatment: A Novel Therapeutic Approach?. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e179-e181.	0.4	7
386	The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group. American Journal of Hematology, 2014, 89, 34-40.	4.1	33
387	Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients. American Journal of Hematology, 2014, 89, 803-808.	4.1	54
388	Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Annals of Oncology, 2014, 25, 195-200.	1.2	126
389	Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood, 2014, 124, 1404-1411.	1.4	138
390	Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients. Blood, 2014, 124, 2113-2113.	1.4	3
391	Growth Differentiation Factor-15 in Patients with Light Chain (AL) Amyloidosis Has Independent Prognostic Significance and Adds Prognostic Information Related to Risk of Early Death and Renal Outcomes. Blood, 2014, 124, 306-306.	1.4	4
392	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. Blood, 2014, 124, 35-35.	1.4	11
393	Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy. Blood, 2014, 124, 4738-4738.	1.4	3
394	Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment. Blood, 2014, 124, 4769-4769.	1.4	1
395	Circulating Levels of Angiogenic Cytokines in Waldenstrom's Macroglobulinemia: Clinical Correlations. Current Angiogenesis, 2014, 2, 104-109.	0.1	0
396	Risk of Progression and Survival in Newly Diagnosed Multiple Myeloma Patients Non-Responsive to Bortezomib-Based Induction Therapy: an Observational Multicenter International Study. Blood, 2014, 124, 3488-3488.	1.4	0

#	Article	IF	CITATIONS
397	Elevated Involved Light Chains Discordant to the Increase of the Involved Heavy Chains Identifies a Subset of Multiple Myeloma Patients with Worse Outcome. Blood, 2014, 124, 2132-2132.	1.4	0
398	High Bone Turnover Is Present in Patients with Primary Systemic (AL) Amyloidosis and Increased Osteoprotegerin Identifies Patients with Poor Survival within Mayo Stage 1 Disease. Blood, 2014, 124, 2028-2028.	1.4	0
399	No Survival Improvement for Central Nervous System Multiple Myeloma By the Use of Novel Anti-Myeloma Agents: The Greek Myeloma Study Group Experience. Blood, 2014, 124, 4752-4752.	1.4	0
400	Hemodynamic, Functional and Structural Markers of Vascular Involvement in Primary Systemic Light Chain (AL) Amyloidosis. Blood, 2014, 124, 2029-2029.	1.4	0
401	The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple Myeloma. Blood, 2014, 124, 3462-3462.	1.4	0
402	Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Is Able to Distinguish Diffuse from Normal MRI Pattern of Marrow Involvement in Patients with Multiple Myeloma. Blood, 2014, 124, 3461-3461.	1.4	1
403	Amplification of 1q21 Is Associated with Other High Risk Cytogenetic Abnormalities and Has No Independent Prognostic Significance in Patients Treated with Novel Agents. Blood, 2014, 124, 3464-3464.	1.4	0
404	Renal Outcomes in Patients with AL Amyloidosis: Evaluation of Prognostic Factors and Impact of Therapy with Novel Agents. Blood, 2014, 124, 2130-2130.	1.4	0
405	Temporal Dynamics of Tumor-Microenvironment Interaction and Treatment Responses Revealed through Time-Lapse Compartment-Specific Bioluminescence Imaging: Translational implications. Blood, 2014, 124, 276-276.	1.4	0
406	Evaluation of Immune Profile in Patients with Multiple Myeloma Using Cytof Technology. Blood, 2014, 124, 3404-3404.	1.4	0
407	Genetic Factors Related with Early Onset of Osteonecrosis of the Jaw in Patients with Multiple Myeloma Under Zoledronic Acid Therapy. Blood, 2014, 124, 2115-2115.	1.4	0
408	Translating Findings of Proteasome Inhibitors Effects from the in VivoDrosophila Experimental Model to Humans: The Paradigm of the Molecular-Cellular Responses to Bortezomib and Carfilzomib. Blood, 2014, 124, 4814-4814.	1.4	0
409	Circulating Adamts-13 Is Reduced in Patients with Waldenstrom's Macroglobulinemia and Is Associated with Increased IgM Levels and Features of the Disease but Not with the Increased Levels of Von Willebrand Factor. Blood, 2014, 124, 5741-5741.	1.4	0
410	Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom Macroglobulinemia. Blood, 2014, 124, 2070-2070.	1.4	0
411	Author's reply: To PMID 23705905. Expert Opinion on Pharmacotherapy, 2014, 15, 300.	1.8	0
412	Proteasome Inhibitor Therapy for Waldenström's Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 235-237.	0.4	6
413	Current treatments for renal failure due to multiple myeloma. Expert Opinion on Pharmacotherapy, 2013, 14, 1477-1495.	1.8	27
414	Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood, 2013, 122, 3276-3282.	1.4	180

#	Article	IF	CITATIONS
415	Response assessment in <scp>W</scp> aldenström macroglobulinaemia: update from the <scp>VI</scp> th <scp>I</scp> nternational <scp>W</scp> orkshop. British Journal of Haematology, 2013, 160, 171-176.	2.5	226
416	Waldenström's Macroglobulinemia. , 2013, , 681-699.		0
417	Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia, 2013, 27, 947-953.	7.2	141
418	The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia, 2013, 27, 423-429.	7.2	137
419	Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. OncoTargets and Therapy, 2013, 6, 531.	2.0	30
420	Reply to S. Girnius et al. Journal of Clinical Oncology, 2013, 31, 2750-2751.	1.6	1
421	Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomideâ€based regimens. American Journal of Hematology, 2013, 88, 765-770.	4.1	40
422	The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC. European Journal of Haematology, 2013, 91, n/a-n/a.	2.2	37
423	A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood, 2013, 121, 3420-3427.	1.4	385
424	How I treat monoclonal gammopathy of renal significance (MGRS). Blood, 2013, 122, 3583-3590.	1.4	259
425	Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece. Cancer Management and Research, 2013, 5, 37.	1.9	19
426	Elevated Von Willebrand Factor Antigen Serum Levels Are Associated With Poor Prognosis In Patients With Symptomatic Waldenstrom's Macroglobulinemia. Blood, 2013, 122, 1860-1860.	1.4	2
427	Vascular Cell Adhesion Molecule-1 Is An Independent Prognostic Factor For Newly-Diagnosed Patients With Multiple Myeloma; Reductions Post VD and Rd In Myeloma Patients At First Relapse. Blood, 2013, 122, 1916-1916.	1.4	1
428	The Novel Proteasome Inhibitors Carfilzomib and Oprozomib Induce Milder Degenerative Effects Compared To Bortezomib When Administered Via Oral Feeding In An In Vivo Drosophila Experimental Model: A Biological Platform To Evaluate Safety/Efficacy Of Proteasome Inhibitors. Blood, 2013, 122, 1930-1930.	1.4	2
429	IgD Myeloma: Clinical Features and Outcome In The Era Of Novel Agents. Blood, 2013, 122, 1935-1935.	1.4	18
430	Skeletal-Related Events In Patients With Multiple Myeloma In The Era Of Novel Agents: Low Incidence Of Pathological Fractures After Treatment. Blood, 2013, 122, 3090-3090.	1.4	4
431	Toll-Like Receptor Activation Promotes Multiple Myeloma Cell Growth and Survival By Suppression Of Endoplasmic Reticulum Stress Factor CHOP. Blood, 2013, 122, 3112-3112.	1.4	1
432	Very Early Death (<2 months) In Myeloma Is Associated With Advanced Age, Poor Performance Status and Reduced Use Of Novel Agents, While Early Death Within 12 Months Is Associated With High Risk Features Of Both The Disease and The Patient. Blood, 2013, 122, 3195-3195.	1.4	5

#	Article	IF	CITATIONS
433	The Cumulative Dose But Not The Frequency Of Infusions Is a Risk Factor For The Development Of Osteonecrosis Of The Jaw (ONJ) In Myeloma Patients Who Receive Zoledronic Acid (ZA). Blood, 2013, 122, 3196-3196.	1.4	1
434	Validation Of Criteria For Renal Response In Patients With Multiple Myeloma (MM) Who Present With Severe Renal Dysfunction. Blood, 2013, 122, 3176-3176.	1.4	1
435	Estimated Glomerular Filtration Rate Calculated By The CKD-EPI Formula Has Improved Prognostic Ability Over MDRD Formula In Patients With Newly Diagnosed, Symptomatic, Multiple Myeloma: Analysis In 1937 Patients. Blood, 2013, 122, 1867-1867.	1.4	1
436	Competing Risk Survival Analysis In Patients With Symptomatic Waldenström's Macroglobulinemia (WM): Disease Unrelated Mortality Accounts For Differences In Survival In Patients >75 Years. Blood, 2013, 122, 3197-3197.	1.4	2
437	Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System?. Blood, 2013, 122, 1866-1866.	1.4	0
438	Genetic Variations In TLR-4/TIRAP Genes Influence Response To IMiDs-Based Regimens and Conventional Chemotherapy In Patients With Multiple Myeloma. Blood, 2013, 122, 1861-1861.	1.4	0
439	Tubular Damage Is Present In Patients With MGUS and Asymptomatic Multiple Myeloma Even In The Absence Of Impaired Estimated Glomerular Filtration Rate; Alterations Of Neutrophil Gelatinase-Associated Lipocalin and Cystatin-C In Myeloma Patients Post IMiD- and Bortezomib-Based Regimens, Blood 2013, 122, 3091-3091	1.4	0
440	Clinical Features, Outcome and Prognostic Factors For Survival and Evolution To Multiple Myeloma Of Solitary Plasmacytomas: A Report Of The Greek Myeloma Study Group In 97 Patients. Blood, 2013, 122, 3130-3130.	1.4	0
441	Multiple Myeloma Patients â‰ ¤ 0 Years Of Age: Clinical Characteristics and Outcome In The Era Of Novel Agents. Blood, 2013, 122, 3226-3226.	1.4	0
442	Elevated Serum Levels Of Von Willebrand Factor (vWF) Predict For Early Death and Shorter Survival In Patients With Primary Systemic Light Chain (AL) Amyloidosis Independently Of Cardiac Biomarkers. Blood, 2013, 122, 3194-3194.	1.4	0
443	Lenalidomide Administration In Patients With POEMS Syndrome. Blood, 2013, 122, 3235-3235.	1.4	1
444	Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. Annals of Oncology, 2012, 23, 2681-2686.	1.2	98
445	When a little aspirin may be enough. Blood, 2012, 119, 905-906.	1.4	5
446	A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood, 2012, 119, 5384-5390.	1.4	88
447	VWF, WM, and angiogenesis: is there a link?. Blood, 2012, 120, 3163-3164.	1.4	2
448	Methyljasmonate displays <i>in vitro</i> and <i>in vivo</i> activity against multiple myeloma cells. British Journal of Haematology, 2012, 159, 340-351.	2.5	26
449	New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes. Journal of Clinical Oncology, 2012, 30, 4541-4549.	1.6	735
450	The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function. Annals of Oncology, 2012, 23, 722-729.	1.2	28

#	Article	IF	CITATIONS
451	Sclerostin: a possible target for the management of cancer-induced bone disease. Expert Opinion on Therapeutic Targets, 2012, 16, 761-769.	3.4	30
452	Evolving Chemotherapy Options for the Treatment of Myeloma Kidney: A 40-Year Perspective. Advances in Chronic Kidney Disease, 2012, 19, 312-323.	1.4	2
453	Prevention and Treatment of Myeloma Bone Disease. Current Hematologic Malignancy Reports, 2012, 7, 249-257.	2.3	11
454	Novel approaches for reducing free light chains in patients with myeloma kidney. Nature Reviews Nephrology, 2012, 8, 234-243.	9.6	37
455	Increased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome. Haematologica, 2012, 97, 1699-1703.	3.5	30
456	Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction postâ€bortezomib monotherapy. International Journal of Cancer, 2012, 131, 1466-1471.	5.1	150
457	Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents. American Journal of Hematology, 2012, 87, 734-736.	4.1	8
458	Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: A single center experience on 228 patients. American Journal of Hematology, 2012, 87, 861-864.	4.1	81
459	Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era. European Journal of Haematology, 2012, 89, 10-15.	2.2	28
460	Circulating angiopoietinâ€1 to angiopoietinâ€2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents. International Journal of Cancer, 2012, 130, 735-742.	5.1	32
461	Semaphorin-4D and Plexin-B1 Are Elevated in Multiple Myeloma Microenvironment and Possibly Contribute in the Development of Lytic Bone Disease. Blood, 2012, 120, 1819-1819.	1.4	7
462	Tubular Damage Is Ubiquitous in Newly-Diagnosed Patients with Multiple Myeloma: Comparison of Three Urinary and Two Serum Markers of Kidney Injury Blood, 2012, 120, 2919-2919.	1.4	3
463	High Levels of Periostin in Patients with Multiple Myeloma Correlate with Low Bone Formation, Increased Fracture Rate and Diffuse MRI Pattern; Implications Into the Biology of Myeloma Bone Disease. Blood, 2012, 120, 3967-3967.	1.4	1
464	Lenalidomide with Low or Intermediate Dose Dexamethasone in Patients with Relapsed or Refractory Myeloma. Blood, 2012, 120, 4028-4028.	1.4	2
465	Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Final Analysis of a Phase II Study. Blood, 2012, 120, 438-438.	1.4	12
466	Waldenström's Macroglobulinemia Associated with Cryoglobulinemia: Pathogenetic, Clinical, and Therapeutic Aspects. , 2012, , 277-283.		0
467	Significant Improvement of the Survival of Patients with Multiple Myeloma Presenting with Severe Renal Impairment After the Introduction of Novel Agents. Blood, 2012, 120, 948-948.	1.4	0
468	Survival until First Progression and Post First Progression Survival Equally Contribute to the Overall Survival of Myeloma Patients: Differences in Patients â‰ ø 5 Years of Age Compared to Patients >65 Years. Blood, 2012, 120, 4030-4030.	1.4	1

#	Article	IF	CITATIONS
469	The Chronic Kidney Disease-Epidemiology Collaboration-Cystatin C (CKD-EPI-CysC) Equation Has an Independent Prognostic Value for Overall Survival in Newly-Diagnosed Patients with Symptomatic Multiple Myeloma: Comparison with 3 Other Equations for GFR Estimation. Blood, 2012, 120, 1849-1849.	1.4	0
470	The Role of Angiopoietins System in Waldenstrom's Macroglobulinemia: Correlations with Marrow Microvessel Density and Survival. Blood, 2012, 120, 3901-3901.	1.4	1
471	Outcomes of Primary Systemic Light Chain (AL) Amyloidosis in Patients Treated Upfront with Novel Agents and the Importance of Risk Adapted Treatment Strategies. Blood, 2012, 120, 1786-1786.	1.4	1
472	High C-Terminal Cross-Linking Telopeptide of Collagen Type-I (CTX) Predicts for Poor Overall Survival in Patients with Multiple Myeloma Who Receive Frontline Therapy with Immunomodulatory Drugs (IMiDs) but Not with Bortezomib-Based Regimens. Blood, 2012, 120, 935-935.	1.4	1
473	Emerging drugs for Waldenström's macroglobulinemia. Expert Opinion on Emerging Drugs, 2011, 16, 45-57.	2.4	5
474	Increased Serum Lactate Dehydrongenase Should Be Included Among the Variables That Define Very-High-Risk Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 409-413.	0.4	39
475	Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens. Leukemia and Lymphoma, 2011, 52, 2299-2303.	1.3	28
476	Expression of CCL3 by Neoplastic Cells in Patients with Waldenström's Macroglobulinemia: An Immunohistochemical Study in Bone Marrow Biopsies of 67 Patients. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 115-117.	0.4	10
477	Prognostication of the High-Risk WM Patient. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 127-129.	0.4	1
478	BET Bromodomain Inhibition asÂa Therapeutic Strategy to Target c-Myc. Cell, 2011, 146, 904-917.	28.9	2,432
479	Systemic Chemotherapy with Pemetrexed and Cisplatin for Malignant Peritoneal Mesothelioma: A Single Institution Experience. Tumori, 2011, 97, 25-29.	1.1	17
480	Bortezomib for AL amyloidosis: moving forward. Blood, 2011, 118, 827-828.	1.4	20
481	Short progressionâ€free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agentâ€based therapy. European Journal of Haematology, 2011, 87, 323-329.	2.2	8
482	Response to bortezomib of a patient with scleromyxedema refractory to other therapies. Leukemia Research, 2011, 35, e209-e211.	0.8	27
483	No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years. American Journal of Hematology, 2011, 86, 479-483.	4.1	43
484	Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias. American Journal of Hematology, 2011, 86, 882-884.	4.1	16
485	Circulating Periostin Is Elevated in Patients with Multiple Myeloma and Correlates with Advanced Disease Features and High Bone Resorption,. Blood, 2011, 118, 3922-3922.	1.4	12
486	Frequency and Prognostic Significance of Hypercalcemia in Patients with Multiple Myeloma: An Analysis of the Database of the Greek Myeloma Study Group. Blood, 2011, 118, 5083-5083.	1.4	4

#	Article	IF	CITATIONS
487	Patients with POEMS Syndrome Have High Bone Turnover and Increased Circulating Angiogenic Cytokines; Should Angiopoietin-2 and Bone-Specific Alkaline Phosphatase Be Used As Minor Criteria for the Diagnosis of the Disease?. Blood, 2011, 118, 806-806.	1.4	1
488	European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease. Blood, 2011, 118, 995-995.	1.4	5
489	The Role of Novel Agents on Reversibility of Renal Impairment in Newly Diagnosed Patients with Multiple Myeloma; a Single Center Experience on 112 Patients,. Blood, 2011, 118, 3961-3961.	1.4	1
490	Clinical Features and Outcome of Newly Diagnosed, Symptomatic Patients with Multiple Myeloma ≥80 Years of Age: An Analysis of the Greek Myeloma Study Group. Blood, 2011, 118, 5084-5084.	1.4	5
491	Characteristics and Clinical Course of Myeloma in Patients 40 Years of Age or Younger: A Study of the Greek Myeloma Study Group. Blood, 2011, 118, 5085-5085.	1.4	0
492	Comparison of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), Modification of Diet in Renal Disease (MDRD) Study Equations and A Formula Based on Cystatin-C and Serum Creatinine for the Estimation of Glomerular Filtration Rate in Patients with Multiple Myeloma; Is It Time to Change From MDRD to CKD-EPI Equation?. Blood, 2011, 118, 5091-5091.	1.4	0
493	Effect of Circulating CCL3, Which Is Produced by Malignant Cells of Waldenstrol`m's Macroglobulinemia, on Patients' Survival. Blood, 2011, 118, 2894-2894.	1.4	Ο
494	Extensive Bone Marrow Infiltration and Abnormal Free Light Chain Ratio Identifies Patients with Smoldering Myeloma At High Risk for Progression to Symptomatic Disease,. Blood, 2011, 118, 3926-3926.	1.4	0
495	Inhibition of c-Myc Expression and Function in Hematologic Malignancies. Blood, 2011, 118, 1409-1409.	1.4	0
496	Circulating Angiogenic Cytokines Are Elevated in Patients with Smoldering Myeloma; Implications Into Disease Biology. Blood, 2011, 118, 5059-5059.	1.4	0
497	Diffuse Pattern of Bone Marrow Involvement in MRI Is Associated with High Risk Cytogenetics and Poor Outcome in Newly Diagnosed, Symptomatic Patients with Multiple Myeloma,. Blood, 2011, 118, 3920-3920.	1.4	0
498	Low Circulating Mannan-Binding Leptin Levels Correlate with Increased Number of Febrile Episodes in Myeloma Patients Who Undergo High Dose Melphalan with Autologous Hematopoietic Stem Cell Transplantation and Do Not Receive Antibiotic Prophylaxis. Blood, 2011, 118, 4457-4457.	1.4	0
499	Prospective Evaluation of the Risk of Thromboembolic Complications in Patients Treated with Lenalidomide-based Therapy and Genetic Associations. Blood, 2011, 118, 2872-2872.	1.4	0
500	Increased Angiogenesis and Enhanced Bone Formation in Patients with IgM Monoclonal Gammopathy and Urticarial Skin Rash: New Insight Into the Biology of the Schnitzler Syndrome. Blood, 2011, 118, 1802-1802.	1.4	0
501	Bone Marrow Biopsy May Be Required During the Initial Evaluation of Individuals with Asymptomatic Monoclonal Gammopathy. Blood, 2011, 118, 5067-5067.	1.4	0
502	Deletion 17p in Unselected Newly Diagnosed Symptomatic Patients with Multiple Myeloma. Blood, 2011, 118, 5081-5081.	1.4	0
503	High Circulating Vascular Endothelial Growth Factor Receptor-1 Correlates with Increased Microvessel Density and Inferior Survival in Newly-Diagnosed Patients with Multiple Myeloma Who Receive Frontline Therapy with Novel Agent-Based Regimens. Blood, 2011, 118, 5082-5082.	1.4	0
504	High Frequency of Monoclonal Immunoglobulins Exhibiting Natural Autoantibody-Like Activity in Patients with Multiple Myeloma and Waldenstroì^m Macroglobulinemia. Blood, 2011, 118, 2893-2893.	1.4	1

#	Article	IF	CITATIONS
505	Effect of Amp5q31 and Del12p13 on Survival of Patients with Multiple Myeloma Treated with Novel Agent-Based Regimens: A Single Center Experience on 172 Patients. Blood, 2011, 118, 1811-1811.	1.4	0
506	Mobilization of Autologous Peripheral Blood Stem Cells with Spectra Optia v5.0: A Single Center Experience with An Automatic Interface-Controlled Apheresis System. Blood, 2011, 118, 4396-4396.	1.4	0
507	Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Cystatin-C Are Sensitive Markers of Renal Injury in Patients with Multiple Myeloma,. Blood, 2011, 118, 3918-3918.	1.4	0
508	Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. European Journal of Haematology, 2010, 85, 1-5.	2.2	28
509	Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stemâ€cell transplantation: Results of a single institution, randomized phase 2 trial. American Journal of Hematology, 2010, 85, 863-867.	4.1	44
510	High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. Leukemia Research, 2010, 34, 399-402.	0.8	26
511	Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). Leukemia Research, 2010, 34, 1340-1343.	0.8	56
512	Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leukemia Research, 2010, 34, 1395-1397.	0.8	64
513	High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients. British Journal of Haematology, 2010, 150, 587-591.	2.5	11
514	Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia, 2010, 24, 1769-1778.	7.2	120
515	Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents. Leukemia, 2010, 24, 1206-1212.	7.2	62
516	Systemic Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1912-1915.	4.5	1
517	Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis. Journal of Clinical Oncology, 2010, 28, 1031-1037.	1.6	273
518	Clinical Characteristics and Outcome of Primary Systemic Light-Chain Amyloidosis in Greece. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 56-61.	0.4	16
519	Bortezomib as a Treatment Option in Patients With Waldenström Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 110-117.	0.4	20
520	High dose melphalan in primary systemic amyloidosis: status quo?. Leukemia and Lymphoma, 2010, 51, 2149-2151.	1.3	0
521	Validation of the Criteria of Response to Treatment In AL Amyloidosis Blood, 2010, 116, 1364-1364.	1.4	19
522	Circulating Levels of the Wnt Inhibitors Dickkopf-1 and Sclerostin In Different Phases of Multiple Myeloma: Alterations Post-Therapy with Lenalidomide and Dexamethasone with or without Bortezomib. Blood, 2010, 116, 2963-2963.	1.4	7

#	Article	IF	CITATIONS
523	Elevated Levels of Circulating Activin-A Correlate with Features of Advanced Disease, Extensive Bone Involvement and Inferior Survival In Patients with Multiple Myeloma. Blood, 2010, 116, 2967-2967.	1.4	4
524	Elevated Serum Lactate Dehydrogenase (LDH) Should Be Included Among the Variables Which Define High Risk Multiple myeloma. Blood, 2010, 116, 2969-2969.	1.4	4
525	Renal Impairment Is Not An Independent Adverse Prognostic Factor In Multiple Myeloma Patients Who Are Treated Upfront with Novel Agent-Based Regimens. Blood, 2010, 116, 3033-3033.	1.4	1
526	The Combination of the Proteasome Inhibitor Bortezomib with Doxorubicin and Dexamethasone (PAD) Tj ETQq0 C Prospective Multicenter Study. Blood, 2010, 116, 3052-3052.) 0 rgBT /0 1.4	Overlock 10 3
527	A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis. Blood, 2010, 116, 988-988.	1.4	25
528	Long Term Follow up of the Combination of Bortezomib with Dexamethasone as Initial Treatment for AL Amyloidosis. Blood, 2010, 116, 3048-3048.	1.4	0
529	Development of New Treatment Strategies Targeting Clonogenic and Tumorigenic Myeloma Side Population Blood, 2010, 116, 1581-1581.	1.4	0
530	Primary Therapy of Waldenstrol`^m's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network. Blood, 2010, 116, 1941-1941.	1.4	3
531	Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor – Microenvironment Interactions Blood, 2010, 116, 1574-1574.	1.4	28
532	Upfront Treatment with Novel Agents Improves the Survival of Symptomatic Patients with Multiple Myeloma Who Are Older Than 65 Years. Blood, 2010, 116, 1947-1947.	1.4	0
533	Increased Expression of Cyclin-D1 on Trephine Bone Marrow Biopsies Independently Predicts for Shorter Overall Survival In Patients with Multiple Myeloma Treated with Novel Agents. Blood, 2010, 116, 2965-2965.	1.4	0
534	Reduced Repair Efficiency Correlates with Increased Cellular Chemosensitivity and Better Response to High Dose Melphalan of Patients with Multiple Myeloma. Blood, 2010, 116, 2976-2976.	1.4	0
535	Short Progression Free Survival Predicts for Poor Overall Survival In Older Patients with Multiple Myeloma Treated Upfront with Novel Agent-Based Therapy. Blood, 2010, 116, 3035-3035.	1.4	0
536	Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's Macroglobulinemia. Journal of Clinical Oncology, 2009, 27, 120-126.	1.6	207
537	VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study. Journal of Clinical Oncology, 2009, 27, 6086-6093.	1.6	154
538	Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration. Haematologica, 2009, 94, 372-379.	3.5	60
539	Somatic mutations of adenomatous polyposis coli gene and nuclear bâ€catenin accumulation have prognostic significance in invasive urothelial carcinomas: Evidence for Wnt pathway implication. International Journal of Cancer, 2009, 124, 103-108.	5.1	57
540	Targeted therapies in multiple myeloma. Targeted Oncology, 2009, 4, 23-36.	3.6	31

#	Article	IF	CITATIONS
541	Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia, 2009, 23, 1152-1157.	7.2	176
542	Increased expression of macrophage inflammatory protein-1α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. Leukemia, 2009, 23, 2177-2181.	7.2	54
543	Angiogenesis in Waldenström's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2009, 9, 46-49.	1.4	12
544	Prognostication in Young and Old Patients with Waldenström's Macroglobulinemia: Importance of the International Prognostic Scoring System and of Serum Lactate Dehydrogenase. Clinical Lymphoma and Myeloma, 2009, 9, 50-52.	1.4	28
545	Rituximab-Based Treatments in Waldenström's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2009, 9, 59-61.	1.4	12
546	Reversibility of Renal Impairment in Patients With Multiple Myeloma Treated With Bortezomib-Based Regimens: Identification of Predictive Factors. Clinical Lymphoma and Myeloma, 2009, 9, 302-306.	1.4	101
547	Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Annals of Oncology, 2009, 20, 117-120.	1.2	347
548	Novel Anti-Myeloma Agents and Bone Metabolism: Implications in the Management of Myeloma Bone Disease. Clinical Lymphoma and Myeloma, 2009, 9, S30-S32.	1.4	0
549	Treatment of Relapsed/Refractory Multiple Myeloma. Seminars in Hematology, 2009, 46, 143-157.	3.4	49
550	Treatment of light chain deposition disease with bortezomib and dexamethasone. Haematologica, 2009, 94, 300-302.	3.5	70
551	The Interaction of Bortezomib with P-Gp, MRP-1 and BCRP Drug Transporters: Implications for Therapeutic Applications of Bortezomib in Advanced Multiple Myeloma and Other Neoplasias Blood, 2009, 114, 1729-1729.	1.4	7
552	The Addition of Bortezomib to the Combination of Lenalidomide and Dexamethasone Increases Bone Formation in Relapsed/Refractory Myeloma: a Prospective Study in 91 Patients Blood, 2009, 114, 1815-1815.	1.4	6
553	Consolidation Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) Regimen After ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Reduces Bone Resorption and RANKL/OPG Ratio but Seems to Have No Effect On Bone Formation and Angiogenesis Blood, 2009, 114, 3863-3863.	1.4	2
554	High Serum Sclerostin Correlates with Advanced Stage, Increased Bone Resorption, Reduced Osteoblast Function, and Poor Survival in Newly-Diagnosed Patients with Multiple Myeloma Blood, 2009, 114, 425-425.	1.4	13
555	A Phase I/II Study of Lenalidomide (R) with Low Dose Dexamethasone (d) and Cyclophosphamide (C) for Patients with Primary Systemic (AL) Amyloidosis Blood, 2009, 114, 428-428.	1.4	3
556	Targeting the Clonogenic Side Population of Multiple Myeloma by Immunomodulatory Drugs (IMiDs) in the Context of Stromal Cell Microenvironment: Pathophysiologic and Clinical Implications Blood, 2009, 114, 954-954.	1.4	2
557	Reversibility of Renal Failure in Newly Diagnosed Patients with Multiple Myeloma and the Role of Novel Agents Blood, 2009, 114, 955-955.	1.4	1
558	Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities Blood, 2009, 114, 958-958.	1.4	4

#	Article	IF	CITATIONS
559	Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica, 2009, 94, 725-728.	3.5	28
560	Increased levels of Vascular Cell Adhesion Molecule-1 (VCAM-1) and Inter-Cellular Adhesion Molecule-1 (ICAM-1) Correlate with Advanced Disease Features and Poor Survival in Newly Diagnosed Patients with Multiple Myeloma. Reduction Post-Bortezomib- and Lenalidomide-Based Regimens Blood, 2009, 114, 1824-1824.	1.4	0
561	Antibacterial Prophylaxis Reduces the Incidence of Neutropenic Fever and the Rate of Infections in Patients with Multiple Myeloma Who Undergo An Autologous Stem Cell Transplantation Blood, 2009, 114, 3334-3334.	1.4	0
562	Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's Macroglobulinemia (WM) and the Importance of Serum Lactate Dehydrogenase (LDH) Blood, 2009, 114, 2845-2845.	1.4	0
563	The Impact of Different Pre-Transplant Regimens Including Novel Agents On Peripheral Blood Mobilization, Harvest, Response and Survival in Patients Undergoing ASCT for Multiple Myeloma. A Single-Center Experience in 210 Patients Blood, 2009, 114, 2279-2279.	1.4	0
564	Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma; Dosing of Lenalidomide According to Renal Function and Effect On Renal Impairment Blood, 2009, 114, 3871-3871.	1.4	0
565	Diffuse MRI Marrow Pattern Correlates with Increased Angiogenesis, Advanced Disease Features and Poor Prognosis in Newly-Diagnosed Patients with Multiple Myeloma Treated with Novel Agents Blood, 2009, 114, 829-829.	1.4	0
566	Methyljasmonate, An Inhibitor of Glycolytic Energy Production, Displays Pre-Clinical Activity against Multiple Myeloma Cells Blood, 2009, 114, 1741-1741.	1.4	0
567	The Transcriptional Signature of Kinases Inhibited by the Multi-Targeted Kinase Inhibitor AS703569 Is Associated with Clinical Outcome in Multiple Myeloma (MM): Anti-MM Activity of AS703569 in Preclinical Studies Blood, 2009, 114, 730-730.	1.4	0
568	Abstract A237: The transcriptional signature of kinases inhibited by the multitargeted kinase inhibitor AS703569 is associated with inferior clinical outcome in multiple myeloma (MM), with promising antiâ€MM activity of AS703569 demonstrated in preclinical studiesin vitroandin vivo. , 2009, , .		0
569	Treatment of plasma cell dyscrasias with lenalidomide. Leukemia, 2008, 22, 1343-1353.	7.2	42
570	Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia, 2008, 22, 1485-1493.	7.2	259
571	The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia, 2008, 22, 2247-2256.	7.2	117
572	Schnitzler's Syndrome: Increased Levels of Bone Formation and Angiogenesis Factors Are Reduced After Successful Pefloxacin Treatment. Clinical Lymphoma and Myeloma, 2008, 8, 359-362.	1.4	13
573	Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leukemia and Lymphoma, 2008, 49, 890-895.	1.3	74
574	Thalidomide plus dexamethasone as primary therapy for newly diagnosed patients with multiple myeloma. Nature Clinical Practice Oncology, 2008, 5, 690-691.	4.3	6
575	Mantle-Cell Lymphoma (Multiple Lymphomatous Polyposis) of the Entire GI Tract. Journal of Clinical Oncology, 2008, 26, 1555-1557.	1.6	22
576	The role of novel drugs in multiple myeloma. Annals of Oncology, 2008, 19, vii121-vii127.	1.2	5

#	Article	IF	CITATIONS
577	Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma. Journal of Clinical Oncology, 2008, 26, 5904-5909.	1.6	139
578	High dose therapy for light chain amyloidosis: Can we reduce treatment related mortality further?. Leukemia and Lymphoma, 2008, 49, 4-5.	1.3	2
579	The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens. Haematologica, 2008, 93, 1420-1422.	3.5	42
580	Reversibility of Renal Impairment of Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Identification of Predictive Factors Blood, 2008, 112, 1725-1725.	1.4	3
581	Bortezomib–Melphalan–Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study Blood, 2008, 112, 1727-1727.	1.4	5
582	Phase I/II Study of Lenalidomide, Intermediate Dose Dexamethasone and Low Dose Cyclophosphamide (RDC) for the Treatment of Patients with Primary Systemic Amyloidosis (AL) Blood, 2008, 112, 1734-1734.	1.4	1
583	Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis. Blood, 2008, 112, 869-869.	1.4	6
584	Increased Levels of Serum Tissue Inhibitor of Metalloproteinase-1 Correlate with Advanced Stage, Increased Bone Resorption, Lytic Bone Disease and Poor Survival in Newly-Diagnosed Myeloma Patients. Blood, 2008, 112, 5143-5143.	1.4	0
585	Osteopontin Predicts for Survival and Cystatin C-Based Estimated GFR Predicts for Renal Response to Therapy in Patients with Primary Systemic Amyloidosis. Blood, 2008, 112, 2731-2731.	1.4	0
586	Strong Correlation Between Angiogenesis and Macrophage Counts in Waldenstrom's Macroglobulinemia: Implications into the Biology of the Disease. Blood, 2008, 112, 5108-5108.	1.4	0
587	Improved Survival of Patients with Multiple Myeloma after the Introduction of Novel Agents and the Applicability of the International Staging System (ISS) An Analysis of the Greek Myeloma Study Group (GMSG). Blood, 2008, 112, 655-655.	1.4	0
588	Immunoexpression of Macrophage Inflammatory Protein-1 Alpha on Bone Marrow Trephine Biopsies Correlates with the Extent of Bone Disease in Newly Diagnosed Patients with Multiple Myeloma. Blood, 2008, 112, 5119-5119.	1.4	0
589	The Administration of Bortezomib, Dexamethasone and Thalidomide (VTD) after ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Normalizes sRANKL, Dickkopf-1 and Improves Abnormal Osteoclast Function and Impaired Angiogenesis Blood, 2008, 112, 1728-1728.	1.4	0
590	Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or with Bortezomib Depending on Prior Neurotoxicity: Prospective Evaluation of the Impact of Cytogenetic Abnormalities and Assessment of Bone Met Blood, 2008, 112, 1726-1726.	1.4	0
591	The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert Opinion on Pharmacotherapy, 2007, 8, 497-509.	1.8	46
592	Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica, 2007, 92, 546-549.	3.5	160
593	Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: Long term follow up and disease control after subsequent treatments. Leukemia and Lymphoma, 2007, 48, 754-758.	1.3	16
594	Biweekly Carboplatin/Gemcitabine in Patients with Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: Report of Efficacy, Quality of Life and Geriatric Assessment. Oncology, 2007, 73, 290-297.	1.9	46

#	Article	lF	CITATIONS
595	Evaluation of the Prognostic and Predictive Value of HER-1/EGFR in Breast Cancer Patients Participating in a Randomized Study with Dose-Dense Sequential Adjuvant Chemotherapy. Oncology, 2007, 72, 388-396.	1.9	16
596	Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica, 2007, 92, 1351-1358.	3.5	179
597	Management of Relapsed and Relapsed Refractory Myeloma. Hematology/Oncology Clinics of North America, 2007, 21, 1175-1215.	2.2	8
598	How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide. Leukemia and Lymphoma, 2007, 48, 2295-2297.	1.3	4
599	Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor–κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncológica, 2007, 46, 221-229.	1.8	83
600	Thalidomide in the treatment of multiple myeloma. Best Practice and Research in Clinical Haematology, 2007, 20, 681-699.	1.7	17
601	Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. British Journal of Haematology, 2007, 137, 560-568.	2.5	37
602	The impact of age in the outcome of patients with advanced or recurrent cervical cancer after platinum-based chemotherapy. Gynecologic Oncology, 2007, 104, 372-376.	1.4	20
603	Cystatin-C Is a Sensitive Marker of Renal Impairment with an Independent Predictive Value for Survival in Multiple Myeloma; Reduction Post Bortezomib Monotherapy Blood, 2007, 110, 1484-1484.	1.4	5
604	Treatment of Light Chain (AL) Amyloidosis and Light Chain Deposition Disease (LCDD) with the Combination of Bortezomib and Dexamethasone Blood, 2007, 110, 191-191.	1.4	1
605	Treatment of Patients with Multiple Myeloma Complicated by Renal Failure with Bortezomib - Based Regimens Blood, 2007, 110, 2739-2739.	1.4	2
606	Long-Term Follow-Up of Multiple Myeloma (MM) Patients (pts) with Osteonecrosis of the Jaw (ONJ) Blood, 2007, 110, 3519-3519.	1.4	11
607	The Combination of Bortezomib, Doxorubicin, and Dexamethasone (PAD) Is an Effective Regimen for High Risk, Newly Diagnosed, Patients with Multiple Myeloma, Reduces Bone Resorption and Normalizes Angiopoietin-1 to Angiopoietin-2 Ratio Blood, 2007, 110, 3596-3596.	1.4	2
608	Decreased Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma (MM) Treated with Zoledronic Acid (ZA) after Application of Preventive Measures Blood, 2007, 110, 3609-3609.	1.4	3
609	Bone Remodeling in Patients with Relapsed/Refractory Multiple Myeloma Who Receive Lenalidomide-Based Regimens Blood, 2007, 110, 4745-4745.	1.4	1
610	Thalidomide Based Regimens (TBR) for Relapsed/Refractory Multiple Myeloma Patients: Long Term Follow Up, Unmaintained Remissions and Disease Control after Subsequent Treatments Blood, 2007, 110, 4812-4812.	1.4	0
611	The International Prognostic Scoring System for Waldestrom's Macroglobulinemia (ISSWM) Is Applicable in Patients Treated with Rituximab-Based Regimens Blood, 2007, 110, 3615-3615.	1.4	0
612	High Serum Levels of Angiogenic Cytokines in AL Amyloidosis Correlates with Disease Features Blood, 2007, 110, 4781-4781.	1.4	0

#	Article	IF	CITATIONS
613	Clinical Characteristics and Outcome of Primary AL Amyloidosis in Greece Blood, 2007, 110, 4729-4729.	1.4	Ο
614	The Ratio of Angiopoietin-1 to Angiopoietin-2 Is Reduced and Predicts Independently for Survival in Newly Diagnosed Patients with Multiple Myeloma Blood, 2007, 110, 1478-1478.	1.4	0
615	Symptomatic Waldenstrom's Macroglobulinemia (WM) in Young Patients: Disease Characteristics and Outcome Blood, 2007, 110, 4730-4730.	1.4	Ο
616	Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome. Anticancer Research, 2007, 27, 611-7.	1.1	12
617	Anthracycline-based adjuvant chemotherapy in early-stage uterine sarcomas: long-term results of a single institution experience. European Journal of Gynaecological Oncology (discontinued), 2007, 28, 109-16.	0.2	2
618	Is there still place for VAD as primary treatment for patients with multiple myeloma who are candidates for high-dose therapy?. Leukemia and Lymphoma, 2006, 47, 2271-2272.	1.3	7
619	Angiogenetic Factors and Biochemical Markers of Bone Metabolism in POEMS Syndrome Treated with High-Dose Therapy and Autologous Stem Cell Support. Clinical Lymphoma and Myeloma, 2006, 7, 73-76.	1.4	17
620	Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel-based chemotherapy. International Journal of Gynecological Cancer, 2006, 16, 994-999.	2.5	26
621	Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenstrom macroglobulinaemia. British Journal of Haematology, 2006, 133, 301-304.	2.5	23
622	Intramedullary spinal cord and leptomeningeal metastases in a patient with carcinoma of the uterine cervix. Gynecologic Oncology, 2006, 102, 124-127.	1.4	15
623	The combination of gemcitabine and carboplatin as firstâ€ŀine treatment in patients with advanced urothelial carcinoma. Cancer, 2006, 106, 297-303.	4.1	78
624	Young Age Is Associated with Favorable Characteristics but Is Not an Independent Prognostic Factor in Patients with Epithelial Ovarian Cancer: A Single Institution Experience. Oncology, 2006, 70, 265-272.	1.9	18
625	Hematological malignancies: myeloma. Annals of Oncology, 2006, 17, x136-x143.	1.2	8
626	The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Regimen for Relapsed/Refractory Myeloma and Reduces Serum Levels of Dickkopf-1, RANKL, MIP-1α and Angiogenic Cytokines Blood, 2006, 108, 3541-3541.	1.4	8
627	Reversibility of Renal Failure in Newly Diagnosed Patients with Multiple Myeloma Treated with High-Dose Dexamethasone Containing Regimens and the Impact of Novel Agents Blood, 2006, 108, 3586-3586.	1.4	1
628	Renal Failure in Multiple Myeloma: Incidence, Correlations and Prognostic Significance Blood, 2006, 108, 5000-5000.	1.4	0
629	Prognostic Significance of Magnetic Resonance Imaging (MRI) of Bone Marrow (BM) in Patients with Multiple Myeloma (MM) Undergoing Treatment with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplantation (ASCT) Blood, 2006, 108, 3095-3095.	1.4	0
630	Diffuse MRI Pattern of Marrow Infiltration Correlates with Suppressed Bone Formation and Increased Incidence of Vertebral Fractures in Multiple Myeloma Blood, 2006, 108, 5018-5018.	1.4	0

#	Article	IF	CITATIONS
631	Angiogenic Cytokines Are Increased in the Serum of Patients with Waldenastrom's Macroglobulinemia (WM): Correlations with Clinical Data Blood, 2006, 108, 5006-5006.	1.4	0
632	Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica, 2006, 91, 968-71.	3.5	223
633	The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy. Anticancer Research, 2006, 26, 3865-9.	1.1	21
634	Carboplatin Hypersensitivity Reactions: A Single Institution Experience. Journal of Chemotherapy, 2005, 17, 104-110.	1.5	16
635	A Phase II Study of Capecitabine Plus Oxaliplatin (XELOX): A New First-Line Option in Metastatic Colorectal Cancer. International Journal of Gastrointestinal Cancer, 2005, 35, 103-110.	0.4	31
636	Clinicopathological features of ovarian carcinosarcomas: a single institution experience. Gynecologic Oncology, 2005, 96, 136-142.	1.4	35
637	The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy. Gynecologic Oncology, 2005, 99, 376-382.	1.4	43
638	Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer, 2005, 103, 2629-2635.	4.1	58
639	The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Annals of Oncology, 2005, 16, 307-313.	1.2	64
640	Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group. Annals of Oncology, 2005, 16, 773-779.	1.2	14
641	Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors. Journal of Clinical Oncology, 2005, 23, 8580-8587.	1.6	990
642	Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: Efficacy, safety, and clinical benefit assessment. Urology, 2005, 65, 126-130.	1.0	26
643	The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Treatment for Relapsed/Refractory Myeloma: Results of a Phase II Clinical Trial Blood, 2005, 106, 363-363.	1.4	13
644	The Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma Who Receive Biphosphonates Depends on the Type of Biphosphonate Blood, 2005, 106, 637-637.	1.4	15
645	Angiogenic Cytokines Are Increased in the Serum of Patients with Waldenstrom's Macroglobulinemia: Correlations with Clinical Data Blood, 2005, 106, 2504-2504.	1.4	0
646	Macrophage Inflammatory Protein-1 alpha (MIP-1α) Is Increased in Patients with Waldenstrom's Macroglobulinemia and Correlates with the Severity of Disease Blood, 2005, 106, 2498-2498.	1.4	13
647	Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterus. European Journal of Gynaecological Oncology (discontinued), 2005, 26, 627-31.	0.2	6
648	Treatment of Relapsed/Refractory Multiple Myeloma with Thalidomide-based Regimens: Identification of Prognostic Factors. Leukemia and Lymphoma, 2004, 45, 2275-2279.	1.3	14

#	Article	IF	CITATIONS
649	Adjuvant Chemotherapy With Paclitaxel and Carboplatin in Patients With Advanced Carcinoma of the Upper Urinary Tract: A Study by the Hellenic Cooperative Oncology Group. Journal of Clinical Oncology, 2004, 22, 2150-2154.	1.6	87
650	A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. Annals of Oncology, 2004, 15, 1250-1255.	1.2	27
651	DIAGNOSIS, RISK-STRATIFICATION, AND MANAGEMENT OF SOLITARY PLASMACYTOMA. , 0, , 150-163.		0
652	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma. , 0, , 121-133.		2